Table 1 Characteristics of patients and primary treatment by Country
Australia/ New Zealand (n =688) | Canada (n =1640) | Central Europea (n =8398) | UK (n =202) | Italy (n=477) | Spain (n =165) | USA (n =1913) | P Value | |
|---|---|---|---|---|---|---|---|---|
Age | . | |||||||
Mean (SD) | 65.0 (6.50) | 64.3 (7.59) | 65.3 (7.27) | 67.0 (7.18) | 65.4 (6.39) | 64.5 (7.88) | 62.9 (7.19) | . <.0001 |
PSA | . | |||||||
PSA ≤ 10 | 546 (81.5%) | 1080 (72.1%) | 5751 (68.6%) | 90 (72.6%) | 358 (75.2%) | 124 (84.4%) | 1431 (82.1%) | <.0001 |
PSA > 10 | 124 (18.5%) | 417 (27.9%) | 2637 (31.4%) | 34 (27.4%) | 118 (24.8%) | 23 (15.6%) | 315 (17.9%) | . |
Missing | 18 | 143 | 10 | 78 | 1 | 18 | 167 | . |
Gleason | . | |||||||
Grade 1 | 301 (43.8%) | 458 (28.1%) | 1829 (21.8%) | 42 (21.0%) | 185 (38.9%) | 86 (52.4%) | 502 (27.8%) | <.0001 |
Grade 2 | 229 (33.3%) | 701 (43.0%) | 3079 (36.7%) | 93 (46.5%) | 120 (25.3%) | 46 (28.0%) | 680 (37.7%) | . |
Grade 3 | 83 (12.1%) | 250 (15.3%) | 1609 (19.2%) | 44 (22.0%) | 72 (15.2%) | 15 (9.1%) | 326 (18.1%) | . |
Grade 4 | 33 (4.8%) | 87 (5.3%) | 1199 (14.3%) | 15 (7.5%) | 72 (15.2%) | 8 (4.9%) | 166 (9.2%) | . |
Grade 5 | 42 (6.1%) | 133 (8.2%) | 681 (8.1%) | 6 (3.0%) | 26 (5.5%) | 9 (5.5%) | 129 (7.2%) | . |
Missing | 11 | 1 | 2 | 2 | 1 | 110 | . | |
Tumor Risk | . | |||||||
Low Risk | 234 (34.0%) | 320 (19.5%) | 1289 (15.3%) | 9 (4.5%) | 139 (29.1%) | 57 (34.5%) | 412 (21.5%) | <.0001 |
Intermediate Risk | 340 (49.4%) | 936 (57.1%) | 4628 (55.1%) | 97 (48.0%) | 201 (42.1%) | 71 (43.0%) | 1035 (54.1%) | . |
High Risk | 85 (12.4%) | 294 (17.9%) | 2309 (27.5%) | 57 (28.2%) | 106 (22.2%) | 24 (14.5%) | 347 (18.1%) | . |
Very High Risk | 3 (0.4%) | 26 (1.6%) | 85 (1.0%) | 13 (6.4%) | 0 (0.0%) | 5 (3.0%) | 0 (0.0%) | . |
Regional | 8 (1.2%) | 10 (0.6%) | 84 (1.0%) | 1 (0.5%) | 29 (6.1%) | 0 (0.0%) | 6 (0.3%) | . |
Unknown | 18 (2.6%) | 54 (3.3%) | 3 (0.0%) | 25 (12.4%) | 2 (0.4%) | 8 (4.8%) | 113 (5.9%) | . |
Comorbidities | . | |||||||
0 comorbidities | 225 (37.9%) | 686 (72.9%) | 5382 (72.3%) | 67 (33.2%) | 184 (41.3%) | 52 (31.5%) | 1286 (69.3%) | <.0001 |
1 comorbidity | 208 (35.0%) | 223 (23.7%) | 1396 (18.8%) | 71 (35.1%) | 205 (46.0%) | 50 (30.3%) | 263 (14.2%) | . |
2+ comorbidities | 161 (27.1%) | 32 (3.4%) | 666 (8.9%) | 64 (31.7%) | 57 (12.8%) | 63 (38.2%) | 307 (16.5%) | . |
Missing | 94 | 699 | 954 | 31 | 57 | . | ||
Primary Treatment | ||||||||
Radical Prostatectomy | 340 (49.4%) | 794 (48.4%) | 7754 (92.3%) | 72 (35.6%) | 414 (86.8%) | 77 (46.7%) | 1643 (85.9%) | |
External Beam Radiotherapy | 104 (15.1%) | 354 (21.6%) | 439 (5.2%) | 53 (26.3%) | 24 (5.0%) | 47 (28.5%) | 16 (0.8%) | |
Brachytherapy | 22 (3.2%) | 83 (5.1%) | 89 (1,1%) | 30 (14.8%) | 0 (0.0%) | 41 (24.8%) | 6 (0.3%) | |
Active Surveillance | 222 (32.2%) | 409 (24.9%) | 116 (1.4%) | 47 (23.3%) | 39 (8.2%) | 0 (0.0%) | 248 (13.0%) |